Biotech Values

[DewDiligence]

As shown in #msg-53349063, MNTA’s effective reimbursement obligation—i.e. the amount MNTA foregoes from Lovenox cash flow relative to what MNTA would have received if there were no reimbursement obligation—is mathematically guaranteed to be proportional to MNTA’s contractual (explicit or implicit) share of Lovenox net profits. Thus, you may stop worrying about what various people said or did not say about this matter on various webcasts.

I honestly can’t tell if you don’t get it because you’re not thinking abstractly enough, or if you do get it and are deliberately spreading FUD. I hope it's the former.